Telomere maintenance in laser capture microdissection - Purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4971-

  Shammas, Masood A ^a   Qazi, Aamer ^a   Batchu, Ramesh B ^a   Bertheau, Robert C ^b   Wong, Jason Y Y ^b   Rao, Manjula Y ^b   Prasad, Madhu ^a   Chanda, Diptiman ^c   Ponnazhagan, Selvarangan ^c   Anderson, Kenneth C ^b   Steffes, Christopher P ^a   Munshi, Nikhil C ^b   Vivo, Immaculata De ^b   Beer, David G ^d   Gryaznov, Sergei ^e   Weaver, Donald W ^a   Goyal, Raj K ^b,f  

^a WAYNE STATE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e GERON CORPORATION   (United States)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; RITONAVIR; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE INHIBITOR GRN163L; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; EPITHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; GROWTH DISORDER; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; SENESCENCE; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CELL AGING; DRUG ANTAGONISM; FEMALE; LASER; METABOLISM; MICRODISSECTION; MOUSE MUTANT; TUMOR CELL LINE; ULTRASTRUCTURE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BARRETT ESOPHAGUS; CELL AGING; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; HUMANS; LASERS; MICE; MICE, SCID; MICRODISSECTION; NEOPLASM TRANSPLANTATION; TELOMERASE; TELOMERE;

EID: 51049105961     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0473     Document Type: Article

References (71)

1. Day JP, Marder BA, Morgan WF. Telomeres and their possible role in chromosome stabilization. Environ Mol Mutagen 1993;22:245-9.
2. Allshire RC, Gosden JR, Cross SH, et al. Telomeric repeat from T. thermophila cross hybridizes with human telomeres. Nature 1988;332:656-9.
3. de Lange T, Shiue L, Myers RM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-27.
4. Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988;85:6622-6.
5. Matulic M, Sopta M, Rubelj I. Telomere dynamics: the means to an end. Cell Prolif 2007;40:462-74.
6. Cong YS, Wright WE, Shay J W. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66: 407-25, table of contents.
7. Akiyama M, Hideshima T, Munshi NC, Anderson KC. Telomerase inhibitors as anticancer therapy. Curr Med Chem Anti-Canc Agents 2002;2:567-75.
8. Shammas MA, Koley H, Batchu RB, et al. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer 2005;4:24.
9. Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munshi NC. Growth arrest, apoptosis, and telomere shortening of Barretts-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 2004;126:1337-46.
10. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271-82.
11. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA [see comments]. Cell 1997;91 25-34.
12. Collins K. Mammalian telomeres and telomerase. Curr Opin Cell Biol 2000;12:378-83.
13. Ducray C, Pommier JP, Martins L, Boussin FD, Sabatier L Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process. Oncogene 1999;18: 4211-23.
14. McEachern MJ, Krauskopf A, Blackburn EH. Telomeres and their control Annu Rev Genet 2000;34: 331-58.
15. De Lange T Telomere-related genome instability tn cancer. Cold Spring Harbor Symp Quant Biol 2005; 70:197-204.
16. Meeker AK. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol 2006;24:122-30.
17. Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006;107: 1391-9.
18. Bisoffi M, Heaphy CM, Griffith JK Telomeres: prognostic markers for solid tumors. Int J Cancer 2006; 119:2255-60.
19. Blackburn EH. Telomerases. Annu Rev Biochem 1992;61:113-29.
20. Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002;12:80-5.
21. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer [see comments]. Science 1994; 266:2011-5.
22. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-60.
23. Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerasedeficient mice. Cell 1999;96:701-12.
24. Lee HW, Blasco MA, Gottlieb GJ, Horner JW II, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392:569-74.
25. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells [see comments] Science 1998;279: 349-52.
26. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements [see comments]. Nature1999;400;464-8.
27. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues Cancer Res 1996;56:645-50
28. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-9.
29. Shay JW. Telomerase in human development and cancer. J Cell Physiol 1997;173;266-70.
30. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer1997;33:787-91
31. Shay JW, Wright WE. The reactivation of telomerase activity in cancer progression. Trends Genet 1996;12: 129-31.
32. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14: 4240-8.
33. Opitz OG, Suliman Y, Hahn WC, Harada H, Blum HE, Rustgi AK. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 2001;108:725-32.
34. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 2001;10:1945-52.
35. Engelhardt M, Martens UM The implication of telomerase activity and telomere stability for replicative aging and cellular immortality (Review). Oncol Rep 1998;5:1043-52
36. Wai LK. Telomeres, telomerase, and tumorigenesis - a review. Med Gen Med 2004;6:19.
37. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA1995;92:9082-6.
38. Masood A, Shammas MA, Shmookler Reis RJ, et al. Telomerase inhibition and cell growth arrest following telomestatin treatment in multiple myeloma. Clin Cancer Res 2004;10:770-6.
39. Shammas MA, Reis RJ, Li C, et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004;10: 770-6.
40. Shammas MA, Shmookler Reis RJ, Akiyama M, et al. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther 2003;2:825-33.
41. Shammas MA, Liu X. Gavory G, Raney KD, Balasubramanian S, Shmookler Reis RJ. Targeting the single-strand G-rich overhang of telomeres with PNA inhibits cell growth and induces apoptosis of human immortal cells. Exp Cell Res 2004;295:204-14.
42. Shammas MA, Simmons CG, Corey DR, Reis RJ. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene 1999;18:6191-200.
43. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998;83:652-9.
44. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42.
45. Swiggers SJ, Nibbeling HA, Zeilemaker A, Kuijpers MA, Mattern KA, ZijImans JM. Telomerase activity level, but not hTERT mRNA and hTR level, regulates telomere length in telomerase-reconstituted primary fibroblasts. Exp Cell Res 2004;297:434-43
46. Huang Q, Yu C, Klein M, Fang J, Goyal RK. DNA index determination with Automated Cellular Imaging System (ACIS) in Barrett's esophagus: comparison with CAS 200. BMC Clin Pathol 2005;5:7.
47. Ohyama H, Zhang X, Kohno Y et al. Laser capture microdissection-generated target sample for highdensity oligonucleotide array hybridization. Biotechniques 2000;29:530-6.
48. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30:e47
49. Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtulla A, Beer DG. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia 2000;2:346-56.
50. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995:92: 9363-7.
51. Bachor C. Bachor OA, Boukamp P. Telomerase is active in normal gastrointestinal mucosa and not upregulated in precancerous lesions. J Cancer Res Clin Oncol 1999;125:453-60.
52. Barclay JY, Morris A, Nwokolo CU. Telomerase, hTERTand splice variants in Barrett's oesophagus and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2005;17:221-7.
53. Going JJ, Fletcher-Monaghan AJ, Neilson L. et al. Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus Neoplasia 2004.6 85-92
54. Yoneyama K. Aoyama N. Koizumi H, Tamai S. [Telo merase activity in esophageal carcinoma and lesions unstained with Lugol's solution] Nippon Rinsho 1998;56:1181 5
55. Harle-Bachor C, Boukamp P. Telomerase activity tn the regenerative basal layer of the epidermis mhuman skin and in immortal and carcinoma-derived skin keratinocytes Proc Natl Acad Sci U S A 1996 93 6476-81
56. Finley JC, Reid BJ, Odze RD. et al Chromosomal instability in Barrett's esophagus is related to telomere shortening Cancer Epidemiol Biomarkers Prev 2006 15:1451-7
57. Bechter OE, Eisterer W. Pall G, Hilbe W, Kuhr T Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res1998;58:4918 22
58. Ohashi K, Tsutsumi M. Kobitsu K. et al. Shortened telomere length in hepatocellular carcinomas and corresponding background liver tissues of patients infected with hepatitis virus Jpn J Cancer Res 1996 87:419-22
59. Odagiri E, Kanada N, Jibiki K. Demura R. Aikawa E. Demura H Reduction of telomenc length and c-erbB 2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia Relationship to histologic grade and clinical parameters. Cancer 1994;73:2978-84
60. Sommerfeld HJ. Meeker AK, Piatyszek MA, Bova GS, Shay JW. Coffey DS. Telomerase activity a prev. alent marker of malignant human prostate tissue Cancer Res 1996;56:218-22
61. Fu W. Begley JG, Killen MW. Mattson MP Antiapoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 1999;274:7264 71
62. Nakajima A, Tauchi T, Sashida G. et al Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy Leuke mia 2003;17:560 7.
63. Seimiya H. Oh-hara T, Suzuki T. et al Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991 Mol Cancer The 2002;1:657-65
64. Munshi NC, Hideshima T Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004.103 1799-806
65. Sumi M, Tauchi T, Sashida G. et al. A G-quadruplexinteractive agent, telomestatin (SOT-095) induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia Int J Oncol 2004;24:1481-7
66. Tauchi T, Shin-Ya K, Sashida G. et al Activity of a novel G-quadruplex-interactive telomerase inhibitor. telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways Oncogene 2003:22 5338-47.
67. Yatabe N. Kyo S, Kondo S. et al. 2 5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells Cancer Gene Ther 2002;9:624-30
68. Akiyama M, Hideshima T. Shammas MA, et al. Effects of oligonucleotide N3′-P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 2003;63:6187 94
69. Herbert BS, Pongracz K, Shay JW, Gryaznov SM Oligonucleotide N3′-P5′ phosphoramidates asefficient telomerase inhibitors. Oncogene 2002;21638 42.
70. Herbert BS, Sanders BG. Kline K N-(4-Hydroxyphenyl)retinamide activation of transforming growth factor-β and induction of apoptosis in human breast cancer cells. Nutr Cancer 1999;34:121-32
71. Shammas MA, Koley H, Bertheau RC. et al. Telomer ase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia Epub 2008 May 1